NZ606964A - A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders - Google Patents

A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Info

Publication number
NZ606964A
NZ606964A NZ606964A NZ60696411A NZ606964A NZ 606964 A NZ606964 A NZ 606964A NZ 606964 A NZ606964 A NZ 606964A NZ 60696411 A NZ60696411 A NZ 60696411A NZ 606964 A NZ606964 A NZ 606964A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
metabolic disorders
methods
treating diabetes
combination pharmaceutical
Prior art date
Application number
NZ606964A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ606964(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of NZ606964A publication Critical patent/NZ606964A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ606964A 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders NZ606964A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
PCT/IB2011/002177 WO2012010966A2 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Publications (1)

Publication Number Publication Date
NZ606964A true NZ606964A (en) 2015-08-28

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ606964A NZ606964A (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Country Status (30)

Country Link
US (1) US8617555B2 (enExample)
EP (2) EP2595658A2 (enExample)
JP (2) JP2013533268A (enExample)
KR (2) KR20130103486A (enExample)
CN (1) CN103118707A (enExample)
AR (1) AR082312A1 (enExample)
AU (1) AU2011281240B2 (enExample)
BR (1) BR112013001299A2 (enExample)
CA (1) CA2805961A1 (enExample)
CL (1) CL2013000200A1 (enExample)
CZ (1) CZ2013124A3 (enExample)
DE (1) DE112011102396T5 (enExample)
DK (1) DK201370089A (enExample)
EA (1) EA029847B1 (enExample)
EE (1) EE05761B1 (enExample)
ES (1) ES2445846R1 (enExample)
FI (1) FI20135152L (enExample)
FR (1) FR2962913A1 (enExample)
GB (2) GB2496799B (enExample)
IT (1) ITTO20110627A1 (enExample)
LT (1) LT5980B (enExample)
MX (1) MX2013000804A (enExample)
MY (1) MY160979A (enExample)
NO (1) NO20130265A1 (enExample)
NZ (1) NZ606964A (enExample)
PE (1) PE20130815A1 (enExample)
PH (1) PH12013500140A1 (enExample)
SE (1) SE1350212A1 (enExample)
SG (1) SG187578A1 (enExample)
WO (1) WO2012010966A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
CZ2013105A3 (cs) * 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Zpusob zvýsení úcinku aktivované potencované formy protilátky
EP2593474A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
DE112011102349T5 (de) 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Zusammensetzung und Behandlungsverfahren
AU2011281247B2 (en) 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
WO2012010970A2 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
BR112013001296A2 (pt) * 2010-07-21 2017-12-19 Lliich Epshtein Oleg composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa
CN103154030A (zh) * 2010-08-06 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对传染性疾病进行治疗和预防的方法
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
TWI345470B (en) 2003-03-14 2011-07-21 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
MXPA06008180A (es) * 2004-01-20 2006-08-31 Astellas Pharma Inc Metodo para tratar disfuncion erectil.
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
CZ2013105A3 (cs) * 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Zpusob zvýsení úcinku aktivované potencované formy protilátky
DE112011102349T5 (de) * 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Zusammensetzung und Behandlungsverfahren
EP2593474A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
BR112013001296A2 (pt) * 2010-07-21 2017-12-19 Lliich Epshtein Oleg composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa
AU2011281247B2 (en) * 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition

Also Published As

Publication number Publication date
ES2445846R1 (es) 2015-01-02
CZ2013124A3 (cs) 2013-06-12
ITTO20110627A1 (it) 2012-01-22
GB201302924D0 (en) 2013-04-03
EP3693018A1 (en) 2020-08-12
CA2805961A1 (en) 2012-01-26
CL2013000200A1 (es) 2015-01-23
EP2595658A2 (en) 2013-05-29
DE112011102396T5 (de) 2013-05-02
CN103118707A (zh) 2013-05-22
SG187578A1 (en) 2013-03-28
GB2552405A (en) 2018-01-24
GB201707872D0 (en) 2017-06-28
AU2011281240A1 (en) 2013-03-07
EA201300124A1 (ru) 2013-12-30
LT5980B (lt) 2013-12-27
US20130064824A1 (en) 2013-03-14
BR112013001299A2 (pt) 2017-11-21
NO20130265A1 (no) 2013-04-18
FI20135152A7 (fi) 2013-02-21
GB2496799B (en) 2017-11-22
FI20135152L (fi) 2013-02-21
SE1350212A1 (sv) 2013-04-22
PE20130815A1 (es) 2013-07-18
DK201370089A (en) 2013-02-19
AU2011281240B2 (en) 2016-07-07
AR082312A1 (es) 2012-11-28
KR20130103486A (ko) 2013-09-23
PH12013500140A1 (en) 2013-03-11
ES2445846A2 (es) 2014-03-05
EA029847B1 (ru) 2018-05-31
EE05761B1 (et) 2016-03-15
MY160979A (en) 2017-03-31
GB2552405B (en) 2018-05-30
FR2962913A1 (fr) 2012-01-27
JP2016222684A (ja) 2016-12-28
WO2012010966A3 (en) 2012-03-29
JP2013533268A (ja) 2013-08-22
GB2496799A (en) 2013-05-22
WO2012010966A2 (en) 2012-01-26
MX2013000804A (es) 2013-10-28
EE201300007A (et) 2013-08-15
KR20180127515A (ko) 2018-11-28
US8617555B2 (en) 2013-12-31
LT2013018A (lt) 2013-10-25

Similar Documents

Publication Publication Date Title
NZ606964A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
NZ606768A (en) Pharmaceutical compositions and methods of treatment
SG10201901167SA (en) Methods and compositions for treatment of attention deficit disorder
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
NZ606977A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
GEP20156319B (en) Asymmetric ureas and medical uses thereof
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
NZ598722A (en) Methods for treating psoriasis
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
GB2496795A (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
IN2014DN09383A (enExample)
UA112981C2 (uk) Варіант людського gdnf
UA64829U (ru) Способ медицинской реабилитации больных послеродовыми психозами
UA53455U (ru) Способ лечения некоторых дерматозов
NZ777266A (en) Treatment of circadian rhythm disorders
UA38766U (en) Combined anesthetic drug
UA38767U (en) Combined anesthetic drug
NZ600486A (en) Pirfenidone treatment for patients with atypical liver function
UA58754U (ru) Способ медицинской реабилитации больных неалкогольным стеатогепатитом на фоне сахарного диабета 2-го типа

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2018 BY FREEHILLS PATENT ATTORNEYS

Effective date: 20160119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2019 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20180622

LAPS Patent lapsed